Ionis Pharmaceuticals Inc... (IONS)
NASDAQ: IONS
· Real-Time Price · USD
32.67
0.14 (0.43%)
At close: May 14, 2025, 3:59 PM
33.00
1.01%
After-hours: May 14, 2025, 07:20 PM EDT
Ionis Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Collaborative Agreement Revenue Revenue | 332.65M | 352.66M | 207.22M | 342.39M | 364.7M | 352.45M | 254.92M |
| Collaborative Agreement Revenue Revenue Growth | -5.67% | +70.18% | -39.48% | -6.12% | +3.48% | +38.26% | n/a |
| Commercial Revenue | 293.08M | 308.59M | 303.36M | n/a | 70M | 42.25M | 2.24M |
| Commercial Revenue Growth | -5.03% | +1.73% | n/a | n/a | +65.67% | +1788.82% | n/a |
| Other Commercial Revenue | 56.78M | 68.21M | 30.05M | n/a | n/a | 292.99M | 237.93M |
| Other Commercial Revenue Growth | -16.76% | +126.99% | n/a | n/a | n/a | +23.14% | n/a |
| Other Revenue | 22.59M | 34.91M | 284.01M | n/a | n/a | n/a | n/a |
| Other Revenue Growth | -35.30% | -87.71% | n/a | n/a | n/a | n/a | n/a |
| Product Revenue | 34.19M | 479.06M | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | -92.86% | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Revenue | 412.06M | 240.38M | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Revenue Growth | +71.42% | n/a | n/a | n/a | n/a | n/a | n/a |
| SPINRAZA Royalties Revenue | 216.09M | n/a | n/a | n/a | n/a | n/a | n/a |
| SPINRAZA Royalties Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 76.25M | 88.1M | 61.6M | 59.53M | 46.99M | 71M | 70M | 46M | 46M | 48M | 34.4M | 33.8M | 34.1M | 38M | 30.1M | 45.1M | 57.1M | 139M | 68.45M | 72.02M | 74.99M | 83M | 60.04M | 76M | 68.22M | 67.1M | 68.71M | 66.2M | 43.65M | 45.71M | 26.79M | 22.32M | 13.68M | 18.04M | 10.19M | 9.82M | 10.56M | 13.18M | 8.75M | 7.78M | 7.47M |
| Selling, General, and Administrative Revenue Growth | -13.45% | +43.02% | +3.47% | +26.69% | -33.81% | +1.43% | +52.17% | 0.00% | -4.17% | +39.53% | +1.78% | -0.88% | -10.26% | +26.25% | -33.26% | -21.02% | -58.92% | +103.08% | -4.95% | -3.97% | -9.65% | +38.25% | -21.01% | +11.40% | +1.67% | -2.34% | +3.80% | +51.65% | -4.49% | +70.62% | +20.03% | +63.17% | -24.20% | +77.10% | +3.71% | -6.99% | -19.87% | +50.62% | +12.55% | +4.14% | n/a |
| Research and Development Revenue | 200.76M | 245.49M | 219.76M | 222.06M | 214.22M | 256.56M | 215M | 230M | 198M | 308M | 182.99M | 180.76M | 161.13M | 179M | 184.77M | 139.31M | 139.8M | 171M | 125.08M | 122.26M | 116.95M | 149M | 104.37M | 106M | 106.42M | 113.45M | 95.25M | 101.83M | 104.07M | 128.28M | 80.21M | 83.51M | 82.64M | 101.15M | 84.63M | 77.57M | 80.96M | 101.33M | 88.51M | 68.01M | 64.45M |
| Research and Development Revenue Growth | -18.22% | +11.71% | -1.04% | +3.66% | -16.50% | +19.33% | -6.52% | +16.16% | -35.71% | +68.32% | +1.23% | +12.18% | -9.99% | -3.12% | +32.64% | -0.35% | -18.25% | +36.71% | +2.31% | +4.54% | -21.51% | +42.77% | -1.54% | -0.39% | -6.20% | +19.10% | -6.46% | -2.15% | -18.88% | +59.93% | -3.94% | +1.05% | -18.30% | +19.52% | +9.10% | -4.19% | -20.10% | +14.49% | +30.15% | +5.52% | n/a |